Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000647933 | SCV000769740 | likely benign | Hereditary spastic paraplegia 3A | 2024-04-25 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002440339 | SCV002748042 | uncertain significance | Inborn genetic diseases | 2019-10-29 | criteria provided, single submitter | clinical testing | The p.N9K variant (also known as c.27C>G), located in coding exon 1 of the ATL1 gene, results from a C to G substitution at nucleotide position 27. The asparagine at codon 9 is replaced by lysine, an amino acid with similar properties. This amino acid position is well conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
ARUP Laboratories, |
RCV005231230 | SCV005876457 | uncertain significance | not provided | 2024-02-15 | criteria provided, single submitter | clinical testing | The ATL1 c.27C>G; p.Asn9Lys variant (rs752593199), to our knowledge, is not reported in the medical literature but is reported in ClinVar (Variation ID: 538580). This variant is observed in the general population with an overall allele frequency of 0.005% (14/280794 alleles) in the Genome Aggregation Database (v2.1.1). Computational analyses predict that this variant is neutral (REVEL: 0.077). Due to limited information, the clinical significance of this variant is uncertain at this time. |